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The current year 2020 will remain in our memory as the one 
marked by the ravaging COVID-19 pandemic and a world-
wide lockdown—the time when our routine activities were 
turned upside down.
Yet, things happen, our patients are still there, studies 
continue to be published.
One of them deserves particular attention, as it brings 
new hope for dialysis patients.
The study, entitled “Sodium thiosulphate and progression 
of vascular calcification in end-stage renal disease patients: 
a double-blind, randomized, placebo-controlled study” was 
published in the first 2020 issue of Nephrology Dialysis 
Transplantation, and selected as “editor’s choice” for this 
issue [1].
In itself, the study is “just” a small randomised controlled 
trial, performed as an exploratory study, and for which 
power calculations were not even done; sixty patients were 
randomised to receive either 25 g/1.73 m2 of sodium thio-
sulphate, or 100 mL of 0.9% sodium chloride, in the last 
fifteen minutes of dialysis. The trial lasted 6 months. Its 
main end-point, reduction of aortic calcifications, was not 
met. However, the patients receiving sodium thiosulphate 
displayed a significant reduction in their iliac artery calcifi-
cations, according to a validated score, while calcifications 
increased, in the meantime, in the patients on placebo. The 
favourable effect was not limited to the iliac arteries, since 
in treated patients arterial stiffness and carotid intima–media 
thickness tended to decrease and there was no increase in 
cardiac valvular calcifications. The latter parameters dis-
played a significant difference between treated and untreated 
patients. The data, as the authors state, are widely scattered, 
and statistical significance is “just met”, if statisticians allow 
a layman’s definition, for the main result of decrease in iliac 
calcifications (− 137 ± 641 versus 245 ± 755; P = 0.049). It 
is therefore quite far from being a perfect trial. However, it 
is an important study, not because of its superb design, or its 
outstanding statistics, but because it introduces an important 
idea, and for the hope it brings.
In fact, the study follows scattered previous evidence sug-
gesting that sodium thiosulphate, the basic treatment for cal-
ciphylaxis may be effective not only in halting progression, 
but also in reversing vascular calcifications [2, 3].
No other treatment has so-far been able to perform this 
miracle: early hope with kidney transplantation was not con-
firmed in the long term, and although parathiroidectomy, 
new phosphate binders and calcimimetics were all able to 
retard the progression of vascular calcifications, none was 
able to set back the biological clock.
Dialysis patients get old too soon. We are pained, often 
overcome with a sense of impotence. each time we see a scan 
of one of our veterans, The patient whose recent CT scan is 
reported in Fig. 1 is almost paradigmatic of this frustrating 
situation: he is relatively young, i.e. in his mid-sixties, has 
a good nutritional status, on target for calcium, phosphate 
and PTH balance (his PTH has remained below 300 ng/mL, 
in keeping with strict Japanese indications).
He has a nearly 30-year history of renal replacement ther-
apy and a failed kidney graft; he is hyperimmunized and 
failed to respond to previous attempts of desensitization. In 
spite of being on on-line high-flow hemodiafiltration with a 
Daugirdas 2 Kt/V of over 1.4, he suffers from disabling dial-
ysis-related amyloidosis. He knows that should his vascular 
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disease progress further, he will not be grafted again. In our 
in-hospital dialysis ward in central France, where the median 
age is approximately seventy-four, and a high percentage of 
patients suffer from diabetes and/or obesity (median Charl-
son Index of 9), over 15% of the patients have experienced 
a minor or major distal amputation. In the last 4 years, ten 
patients experienced one episode of calciphylaxis and were 
treated with sodium thiosulphate. As in the study being 
discussed here, no severe side effects were found, provided 
dialysate sodium had been adjusted to avoid overload.
In addition to the two studies cited in the paper, in which, 
respectively, eighty-six patients were treated for 4 months 
and twenty-two patients for 5 months, both reporting posi-
tive results without relevant side effects, we were able 
to retrieve three further studies that, albeit with different 
deigns, reported, once more in the absence of relevant side 
effects, a positive effect on arterial stiffness (in twenty-four 
patients randomised for receiving treatment for 5 months 
[4]), leg pain related with vascular calcifications (18 heavily 
calcified patients, treated for 6 months [5]), and coronary 
artery calcifications (17 patients treated for 3 months [6]). In 
one further study, in which sodium thiosulphate was added 
to the dialysis fluid, a “positive impression” was reported in 
six cases [7]. Significantly, the data are in keeping with the 
few, albeit convincing, animal and in vitro studies published.
Why were these promising studies not followed up? 
Sodium thiosulphate is not expensive, at least in Europe; 
it is readily available, provided that the pharmacy cooper-
ates in its preparation, and can be safely handled, provided 
that attention is paid to the management of the dialysis ses-
sion. In patients with calciphylaxis, in our center we per-
fuse a standard dose of 25 g in the last thirty minutes of 
dialysis, modulating sodium and bicarbonate concentration 
in the dialysate. While this simple manoeuvre is not time 
consuming, attention is needed, and this may be perceived 
as “complicated” in an overcrowded dialysis ward.
As usual, in this era of evidence-based medicine, the 
question that arises is whether we should wait for a “per-
fect”, large-scale randomised controlled trial, or for irrefu-
table evidence on the promising new alternatives [8], or, in 
the absence of alternatives, and, more importantly, in the 
absence of severe side effects of a drug we routinely use 
with slightly different indications [9],we should wisely select 
those of our patients who would, to the best of our clinical 
knowledge, benefit more from halting or regressing vascular 
calcifications?
There is no “right answer” to this question; however, to 
cite a pivotal paper that appeared in 2002 in The BMJ, “Evi-
dence does not make decisions, people do”. We wholeheart-
edly agree.
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